“In conclusion, maintenance of effective anticancer activity of lower doses of sorafenib against thyroid cancer cells may be obtained by the co-administration of quercetin.”
“In this work, we investigated the effects of coadministration of quercetin and sorafenib on the proliferation, adhesion and migration properties of two different papillary thyroid cancer cell lines, to test the validity of this association to maintain the anticancer effects of sorafenib with lower dosage.”
“K1 and BCPAP cells treated with sorafenib 0.1 μM and quercetin 25 μM for 24 h showed a decrease in the cell proliferation rate (~70% vs untreated cells vs. ~30% reduction of sorafenib alone).”